Celiac Disease: Advances in Treatment via Gluten Modification

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 8, 2012, Pages 859-862

  Stoven, Samantha ^a   Murray, Joseph A ^a,b   Marietta, Eric ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Autoimmune; Celiac; Gluten; Therapies; Treatment

Indexed keywords

ALV 003 ENZYME; AN PEP ENZYME; GLUTEN; MICROBIAL ENZYME; POLY(HYDROXYETHYL METHACRYLATE CO STYRENE SODIUM SULFONATE); POLYMER; STAN 1 ENZYME; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS NIGER; CELIAC DISEASE; CHRYSEOBACTERIUM MENINGOSEPTICUM; ENZYME THERAPY; FLOUR; GLUTEN FREE DIET; HUMAN; MYXOCOCCUS XANTHUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SPHINGOMONAS; SPHINGOMONAS CAPSULATE; TRITICUM AESTIVUM;

CELIAC DISEASE; DIET, GLUTEN-FREE; DIETARY SUPPLEMENTS; ENZYME THERAPY; GLUTENS; HUMANS;

EID: 84864109994     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.06.005     Document Type: Article

References (24)

1. van den Broeck H.C., van Herpen T.W., Schuit C., et al. Removing celiac disease-related gluten proteins from bread wheat while retaining technological properties: a study with Chinese Spring deletion lines. BMC Plant Biol 2009, 9:41.
2. Frisoni M., Corazza G.R., Lafiandra D., et al. Wheat deficient in gliadins: promising tool for treatment of coeliac disease. Gut 1995, 36:375-378.
3. Carroccio A., Di Prima L., Noto D., et al. Searching for wheat plants with low toxicity in celiac disease: between direct toxicity and immunologic activation. Dig Liver Dis 2011, 43:34-39.
4. Spaenij-Dekking L., Kooy-Winkelaar Y., van Veelen P., et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005, 129:797-806.
5. Tye-Din J.A., Anderson R.P., Ffrench R.A., et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010, 134:289-295.
6. Gass J., Bethune M.T., Siegel M., et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007, 133:472-480.
7. Ehren J., Morón B., Martin E., et al. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS ONE 2009, 4:e6313.
8. Catassi C., Fabiani E., Iacono G., et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007, 85:160-166.
9. Ciacci C., Maiuri L., Caporaso N., et al. Celiac disease: in vitro and in vivo safety and palatability of wheat-free sorghum food products. Clin Nutr 2007, 26:799-805.
10. Molberg O., Uhlen A.K., Jensen T., et al. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005, 128:393-401.
11. Di Cagno R., De Angelis M., Auricchio S., et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004, 70:1088-1096.
12. Di Cagno R., Barbato M., Di Camillo C., et al. Gluten-free sourdough wheat baked goods appear safe for young celiac patients: a pilot study. J Pediatr Gastroenterol Nutr 2010, 51:777-783.
13. di Cagno R., de Angelis M., Alfonsi G., et al. Pasta made from durum wheat semolina fermented with selected lactobacilli as a tool for a potential decrease of the gluten intolerance. J Agric Food Chem 2005, 53:4393-4402.
14. Greco L., Gobbetti M., Auricchio R., et al. Safety for patients with celiac disease of baked goods made of wheat flour hydrolyzed during food processing. Clin Gastroenterol Hepatol 2011, 9:24-29.
15. Gianfrani C., Siciliano R.A., Facchiano A.M., et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 2007, 133:780-789.
16. Siegel M., Garber M.E., Spencer A.G., et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012, 57:440-450.
17. Stepniak D., Spaenij-Dekking L., Mitea C., et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006, 291:G621-G629.
18. Mitea C., Havenaar R., Drijfhout J.W., et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008, 57:25-32.
19. Evaluation of patient reported outcome instruments in celiac disease patients Alvine Pharmaceuticals, NLM Identifier: NCT01560169. Accessed April 16, 2012. http://clinicaltrials.gov/show/NCT01560169.
20. Lahdeaho M., Maki M., Kaukinen K., et al. ALV003, a novel glutenase, attenuates gluten-induced small intestinal mucosal injury in celiac disease patients: a randomized controlled phase 2A clinical trial. Gut 2011, 60:A12.
21. DSM Food Specialties. Effect of AN-PEP enzyme on gluten digestion NLM Identifier: NCT01335503. Accessed April 16, 2012. http://clinicaltrials.gov/show/NCT01335503.
22. Effect of Aspergillus niger prolyl endoprotease (AN-PEP) enzyme on the effects of gluten ingestion in patients with coeliac disease VU University Medical Center, NLM Identifier: NCT00810654Accessed April 16, 2012. http://clinicaltrials.gov/show/NCT00810654.
23. Korponay-Szabo I.R., Tumpek J., Gyimesi J., et al. Food-grade gluten degrading enzymes to treat dietary transgressions in coeliac adolescents. J Pediatr Gastroenterol Nutr 2010, 50:E68.
24. Pinier M., Fuhrmann G., Galipeau H.J., et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012, 142:316-325.